AiCure is an artificial intelligence (AI) and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. This is completed through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing to confirm medication adherence. Founded in 2010, AiCure has received funding from the National Institutes of Health (NIH), as well as other investors. In recent years, AiCure has focused in part on applications for oncology clinical trials.
How it works
The AiCure’s dosing support solution works through an application on a patient’s smartphone. The system alerts patients when it’s time to take medication and walks them through how to do so correctly. The smartphone’s recording features work with AiCure’s artificial intelligence program to confirm whether a dose has been taken. This information is transmitted to the patient’s care team.
AiCure has been scored below according to it’s ability to serve the TB market for low- and middle-income countries (LMICs) along Fit for Purpose and Technical Specifications metrics. Note that higher scores equate to a greater ability to serve the market. For example, if a product scores well in the Provider Burden subcategory, that means that the burden for the provider is low.
For full descriptions of the sub-categories, see the 2021 DAT Market Landscape.
Fit for Purpose
Barriers to Entry100%
- High level of pill-taking accuracy
- Does not require a provider to confirm that doses were taken
- Has been used previously for tuberculosis treatment
- Requires a smartphone
- Does not allow export of data to other platforms
- Has not been used for TB treatment in LMICs